Research Peptide · For Laboratory Use Only

Retatrutide 10mg

Triple GIP/GLP-1/Glucagon Receptor Agonist · 39-Amino-Acid Fatty-Acid-Conjugated Peptide · Lyophilized Powder · Purity ≥99% (HPLC)

Retatrutide (development code LY3437943) is a single-molecule triple hormone receptor agonist that simultaneously activates the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR) — the first peptide of its class to reach late-stage clinical development. Its 39-amino-acid backbone carries a distinctive set of stability modifications: two α-aminoisobutyric acid (Aib) residues that block DPP-4-type cleavage and an α-methyl-leucine (α-Me-Leu) that reinforces the helical pharmacophore against proteolysis. A C20 fatty diacid is conjugated to a lysine side chain through a hydrophilic γ-Glu-AEEA-AEEA linker, enabling reversible albumin binding and once-weekly pharmacokinetics.

In clinical research, retatrutide has produced the largest body-weight reductions reported for any incretin-based therapy to date — up to approximately 24% at 48 weeks in Phase 2 and around 28% in Phase 3 trials — by combining appetite suppression (GLP-1R), insulin sensitization and lipid handling (GIPR), and glucagon-driven energy expenditure and hepatic fat oxidation (GCGR). Each vial is supplied as a sterile lyophilized (freeze-dried) powder to ensure maximum stability.

• Lyophilized powder: Store at -20°C for long-term stability; 2–8°C is acceptable for short-term storage. Avoid repeated temperature cycling and protect from light and moisture.
• Before opening: Allow the vial to reach room temperature and briefly centrifuge to ensure the full contents collect at the bottom of the vial.
• Reconstitution: Add bacteriostatic water or an appropriate solvent gently along the vial wall. Swirl slowly until fully dissolved; avoid vigorous shaking. As a lipidated amphipathic peptide, retatrutide may dissolve slightly slower than small peptides — patient, gentle swirling is recommended.
• Reconstituted solution: Store at 2–8°C, protect from light, and use promptly; do not refreeze the solution.
• General: Handle with standard laboratory protective equipment (gloves, lab coat, eye protection).

Q1: How is retatrutide different from tirzepatide and semaglutide?

A: They represent three generations of incretin-based design. Semaglutide is a selective GLP-1 receptor agonist; tirzepatide adds GIP receptor activity (dual agonist); retatrutide adds glucagon receptor activity on top of both (triple agonist). The glucagon component contributes increased energy expenditure and hepatic fat oxidation — a mechanism absent from the first two generations — which is reflected in the larger weight reductions observed in clinical trials.

Q2: Why does retatrutide contain the unusual modifications Aib and α-Me-Leu?

A: Both are non-coded amino acids used to defeat enzymatic degradation. Aib (α-aminoisobutyric acid) blocks DPP-4-type cleavage near the N-terminus, while α-methyl-leucine stabilizes the helical pharmacophore and resists proteolysis. Together with the albumin-binding fatty acid chain, they enable the once-weekly pharmacokinetic profile.

Q3: Isn't glucagon a blood-sugar-raising hormone — why agonize its receptor?

A: This is a deliberate and much-studied design choice. In the context of concurrent GLP-1R and GIPR agonism (which strongly control glycemia), GCGR activation contributes increased energy expenditure, lipid oxidation and liver-fat reduction without the glycemic liability that unopposed glucagon would cause. Retatrutide's balanced receptor potencies were tuned specifically to capture this synergy.

Q4: What is the development status of retatrutide?

A: Retatrutide is an investigational compound in Phase 3 clinical trials (TRIUMPH program) for obesity, type 2 diabetes and liver-fat-related indications. It is not an approved pharmaceutical product anywhere for the purposes sold here.

Q5: How should I store it after receiving?

A: Keep unopened vials at -20°C for long-term storage. Once reconstituted, refrigerate at 2–8°C, protect from light, and use promptly; do not refreeze the solution.

Q6: Is a Certificate of Analysis (COA) available?

A: Yes, third-party tested COA documentation can be provided for each batch. Please contact our customer service with your order number.

⚠ Research Use Only — Disclaimer

All product information provided on this page is solely for information dissemination and educational purposes. The products offered are intended exclusively for in vitro laboratory research and are not pharmaceuticals. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for the purposes sold here, and must not be used to prevent, treat or cure any medical condition, disease or ailment.

It is strictly prohibited to introduce these products into the human or animal body in any form. By purchasing, the buyer acknowledges full responsibility for the proper handling, use and compliance with all applicable local laws and regulations.